secwatch.observer — SEC 8-K summary
======================================

Issuer:     ClearPoint Neuro, Inc. (CLPT)
CIK:        0001285550
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001285550-23-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ClearPoint Neuro Q1 revenue $5.4M (+8% YoY); biologics/drug delivery +24%; reaffirms FY23 guidance $25-27M
--------------------------------------------------------------------------------

- Revenue $5.4M (+8% YoY); biologics and drug delivery revenue $2.7M (+24% YoY) drove growth.
- Gross margin fell to 59% from 64% due to higher biologics services costs and overhead.
- Operating expenses $8.9M vs $7.1M, driven by headcount and stock-based compensation increases.
- Cash and short-term investments $31.7M, down from $37.5M; operating cash used $5.7M in quarter.
- Reaffirmed full-year 2023 revenue guidance of $25-27M, implying 22-35% YoY growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285550/000128555023000045/0001285550-23-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285550/000128555023000045/clpt-20230511.htm
  HTML page:      https://secwatch.observer/filing/0001285550-23-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer